Total Payments
$377,203
2024 Payments
$20,833
Companies
14
Transactions
172
Medicare Patients
1,300
Medicare Billing
$162,958
Payment Breakdown by Category
Other$203,313 (53.9%)
Consulting$148,607 (39.4%)
Travel$12,013 (3.2%)
Research$9,644 (2.6%)
Food & Beverage$3,627 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200,013 | 14 | 53.0% |
| Consulting Fee | $148,607 | 44 | 39.4% |
| Travel and Lodging | $12,013 | 51 | 3.2% |
| Unspecified | $9,644 | 3 | 2.6% |
| Food and Beverage | $3,627 | 59 | 1.0% |
| Honoraria | $3,300 | 1 | 0.9% |
Payments by Type
General
$367,559
169 transactions
Research
$9,644
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $173,423 | 6 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $35,277 | 29 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $33,145 | 8 | $0 (2021) |
| Exelixis Inc. | $28,933 | 28 | $0 (2022) |
| Eisai Inc. | $27,347 | 32 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $23,903 | 16 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $17,599 | 18 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $12,357 | 15 | $0 (2021) |
| Aveo Pharmaceuticals, Inc. | $9,644 | 3 | $0 (2022) |
| Eli Lilly and Company | $4,888 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,833 | 13 | AstraZeneca Pharmaceuticals LP ($16,649) |
| 2023 | $10,035 | 8 | AstraZeneca Pharmaceuticals LP ($7,255) |
| 2022 | $14,014 | 6 | Aveo Pharmaceuticals, Inc. ($9,644) |
| 2021 | $33,968 | 9 | E.R. Squibb & Sons, L.L.C. ($20,625) |
| 2020 | $14,103 | 6 | Exelixis Inc. ($5,940) |
| 2019 | $30,800 | 48 | EISAI INC. ($8,440) |
| 2018 | $65,727 | 55 | Lilly USA, LLC ($20,683) |
| 2017 | $187,724 | 27 | Lilly USA, LLC ($152,740) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,330.00 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $8,200.00 | General |
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $116.81 | General |
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $95.78 | General |
| Category: Oncology | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $409.51 | General |
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $170.00 | General |
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $56.66 | General |
| 11/06/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $64.58 | General |
| Category: Oncology | ||||||
| 07/24/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,829.05 | General |
| Category: Oncology | ||||||
| 05/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $120.65 | General |
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $147.05 | General |
| Category: Interventional Oncology | ||||||
| 11/17/2023 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Interventional Oncology | ||||||
| 11/17/2023 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Travel and Lodging | Cash or cash equivalent | $33.64 | General |
| Category: Interventional Oncology | ||||||
| 11/09/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 11/01/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.81 | General |
| 10/25/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 08/30/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Oncology | ||||||
| 05/31/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 11/04/2022 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| Category: Oncology | ||||||
| 10/27/2022 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma • Category: Oncology | ||||||
| 10/27/2022 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma • Category: Oncology | ||||||
| 09/30/2022 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | Aveo Pharmaceuticals, Inc. | $9,644 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 353 | 582 | $241,924 | $45,676 |
| 2022 | 7 | 338 | 573 | $227,877 | $44,403 |
| 2021 | 8 | 302 | 488 | $153,477 | $35,737 |
| 2020 | 9 | 307 | 530 | $151,519 | $37,142 |
Total Patients
1,300
Total Services
2,173
Medicare Billing
$162,958
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 54 | 117 | $48,001 | $9,563 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 102 | $41,606 | $8,119 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 95 | $26,258 | $5,131 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 63 | 89 | $24,688 | $4,636 | 18.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 62 | $17,236 | $4,136 | 24.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $21,318 | $3,300 | 15.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $19,586 | $3,270 | 16.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 19 | $13,818 | $2,329 | 16.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 20 | 20 | $14,384 | $2,276 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $11,376 | $2,011 | 17.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 13 | $3,653 | $905.06 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 53 | 100 | $40,008 | $8,306 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 99 | $39,613 | $7,966 | 20.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 30 | 98 | $27,244 | $5,892 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 69 | 103 | $27,909 | $5,549 | 19.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 35 | 35 | $24,402 | $4,079 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 61 | $16,509 | $3,123 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $14,703 | $2,688 | 18.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $12,977 | $2,377 | 18.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 15 | $10,686 | $1,886 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $9,049 | $1,483 | 16.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 17 | 17 | $4,777 | $1,053 | 22.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 50 | 84 | $29,116 | $6,665 | 22.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 68 | 117 | $26,622 | $6,279 | 23.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 86 | $19,764 | $4,939 | 25.0% |
About Dr. Thomas Abrams, M.D
Dr. Thomas Abrams, M.D is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184693947.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Abrams, M.D has received a total of $377,203 in payments from pharmaceutical and medical device companies, with $20,833 received in 2024. These payments were reported across 172 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($200,013).
As a Medicare-enrolled provider, Abrams has provided services to 1,300 Medicare beneficiaries, totaling 2,173 services with total Medicare billing of $162,958. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 03/15/2006
- Last Updated 08/13/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1184693947
Products in Payments
- Lenvima (Drug) $27,347
- Stivarga (Drug) $26,718
- Cabometyx (Drug) $25,903
- OPDIVO (Biological) $24,675
- ONIVYDE (Drug) $13,136
- FOTIVDA (Drug) $9,644
- IMFINZI (Biological) $9,471
- Nexavar (Drug) $8,559
- Onivyde (Drug) $4,413
- TIBSOVO (Drug) $3,942
- Abraxane (Drug) $3,066
- SIR-Spheres Microspheres (Device) $2,781
- CABOMETYX (Drug) $1,980
- KEYTRUDA (Biological) $1,125
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701